ViaCyte, Inc.

141 articles about ViaCyte, Inc.

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Achieves Significant Milestone With ISO 13485:2003 Certification For Its Encaptra Drug Delivery System

  7/8/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Appoints Mark Foletta, Former CFO Of Amylin Pharmaceuticals, Inc., To Its Board Of Directors

  12/18/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At The 25th Piper Jaffray Healthcare Conference

  12/3/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine

  10/30/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) to Present at the JDRF 8th Annual T1D Global Path to a Cure Symposium

  10/16/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) to Present Update on VC-01™ Combination Product Development at 2013 Stem Cell Meeting on the Mesa

  10/11/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Nabs $10.6 Million in a Private Financing

  7/10/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.)'s Role as a Leading Cell Therapy Company Bolstered With the Issuance of 20 Patents in 2012

  1/31/2013

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Appoints Steve Altman to Its Board of Directors

  10/29/2012

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Gets $10.1 Million State Stem Cell Agency Grant for Artificial Pancreas

  10/26/2012

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Appoints Dr. Paul Laikind Chief Executive Officer

  6/15/2012

• JDRF to Support ViaCyte, Inc. (Formerly Known as Novocell, Inc.)'s Development of Innovative Encapsulated Beta Cell Replacement Therapy for Diabetes

  12/14/2011

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Executive Management Changes

  8/9/2011

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Names Michael Scott Vice President, Device Research & Development

  6/16/2011

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.), Names Anthony Gringeri Chief Development Officer

  5/13/2011

• Cellular Dynamics International Licenses Technology From ViaCyte, Inc. (Formerly Known as Novocell, Inc.)

  4/13/2011

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.), Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes

  5/6/2010

• Novocell Becomes ViaCyte, Inc. (Formerly Known as Novocell, Inc.), as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes

  5/6/2010

• Novocell, Inc. Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes

  10/29/2009

• Novocell, Inc. Obtains U.S. Patent for Drug Screening Human Embryonic Cell Derived-Endoderm Cells

  6/3/2009